{"entity":{"id":"nct05932212","kind":"trial","name":"AK104 for Recurrent or Metastatic Vulvar Cancer","aka":[],"tldr":"A phase 2 trial of Cadonilimab, Paclitaxel / nab-paclitaxel in vulvar cancer, run by Akeso, now recruiting.","summary":"AK104 for Recurrent or Metastatic Vulvar Cancer is a phase 2 interventional study registered as NCT05932212 by Akeso, with 20 participants planned, started 2023-08-25 and due to reach its primary completion in 2025-12-15. Interventions recorded: AK104, AK104+ Paclitaxel+Cisplatin or Carboplatin. Conditions listed: Vulvar Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05932212","url":"https://clinicaltrials.gov/study/NCT05932212"}],"tags":["ctgov-ingest"],"related":[],"cancers":["vulvar","hpv-associated-vulvar-cancer","hpv-independent-vulvar-cancer"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor"],"targets":[],"drugs":["cadonilimab","paclitaxel"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05932212","phase":"2","setting":"A Multicenter, Open-label, Phase II Study of AK104 in the Treatment of Recurrent or Metastatic Vulvar Cancer","sponsor":"Akeso","started":"2023-08-25","startedType":"actual","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05932212/","neighbours":{"cancer":[{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/"},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/"},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}